FDA should be way more stringent about drug approval: "93 cancer drug indications granted accelerated approval by the FDA from December 11, 1992, through May 31, 2017, confirmatory trials reported that 20% (n = 19) had improvement in overall survival"https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2733561 …
-
-
This article doesn't say they are meaningless if you're a patient. It's more nuanced than that. "We defend the position that surrogate endpoints can and should be used for regulatory or clinical practice decision-making in specific circumstances".
-
Everything is more nuanced if you look close enough. In the overwhelming majority of cases, for the overwhelming majority of patients, they do not mean better or longer lives
Kraj razgovora
Novi razgovor -
-
-
If I were a patient (& my doctor explained the uncertainty) I might ask this: I get that this potentially curative or life-extending therapy hasn't been proven as such. What are the odds it will be? What is the past track record of therapies in similar states of uncertainty?
-
The correlation with OS is modest. Most oncologists don't realize this.https://www.sciencedirect.com/science/article/pii/S095980491831476X …
- Još 1 odgovor
Novi razgovor -
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.